OmniAb, Inc. (OABI)
(Delayed Data from NSDQ)
$4.28 USD
+0.21 (5.16%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $4.28 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
OABI 4.28 +0.21(5.16%)
Will OABI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for OABI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for OABI
USANA Health Sciences (USNA) Q1 Earnings and Revenues Top Estimates
Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates
OABI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates
OmniAb, Inc. (OABI) Soars 10.5%: Is Further Upside Left in the Stock?
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates
Other News for OABI
Analysts Offer Insights on Healthcare Companies: Illumina (ILMN) and OmniAb (OABI)
Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX), OmniAb (OABI) and Syndax Pharmaceuticals (SNDX)
Analysts Offer Insights on Healthcare Companies: OmniAb (OABI), Avadel Pharmaceuticals (AVDL) and Regulus (RGLS)
OmniAb, Inc. 2024 Q2 - Results - Earnings Call Presentation
OmniAb, Inc. (OABI) Q2 2024 Earnings Call Transcript